Skip to main content
. 2018 Oct 2;42(6):3083–3092. doi: 10.3892/ijmm.2018.3914

Figure 6.

Figure 6

BML-111 treatment inhibited α-SMA expression and ECM deposition in lungs following BLM injection. Mice treated with 50 µl saline (Sham group) or 2 mg/kg BLM (untreated group, BML-111 group and BOC-2 group) at day 0 were intraperitoneally injected with 1 ml saline (Sham and untreated group) or 1 mg/kg of BML-111 (BML-111 group and BOC-2 group) with or without 50 µg/kg BOC-2 (BOC-2 group) every other day from day 0-21. Mice were sacrificed on day 21 and the expression of (A and B) α-SMA and (C) fibronectin was detected using western blotting. (D) Total collagen protein was measured using a Sircol collagen assay kit, and the content of (E) hydroxyproline was determined using a Hydroxyproline assay kit. Data are expressed as mean ± standard deviation. ##P<0.01 vs. the Sham group. +P<0.05 and ++P<0.01 vs. the untreated group. *P<0.05, **P<0.01 vs. the BML-111 group. α-SMA, smooth muscle α actin; ECM, extracellular matrix; BLM, bleomycin.